 - Clinical stage II or stage III triple-negative ER andor PR no staining or weak staining in less than or equal to 10 cells by immunohistochemistry IHC and HER2-negative by Herceptest 0, 1 or FISH invasive mammary carcinoma, confirmed by histological analysis. 